XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATIONThe Company's shareholders approved the 2018 Omnibus Equity Incentive Plan (the "Plan"), which authorizes the granting of incentive stock options, supplemental stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), other stock-based awards and cash-based awards to officers, employees and non-employee directors of, and consultants and advisors to, the Company and its subsidiaries. The Company previously granted such awards under the 2009 Equity Compensation Program; however, no further awards may be granted from the 2009 program.
Restricted Stock
The following is a summary of the Company’s restricted stock activity during the nine months ended September 30, 2020:
Number of
Shares
Weighted
Average
Price
Outstanding, January 1, 202013,110 $15.93 
Granted13,041 16.87 
Vested(13,052)15.96 
Outstanding, September 30, 202013,099 $16.83 
In the first nine months of 2020, the Company granted 13,041 shares of restricted stock to non-employee directors at a grant date fair value of $16.87 per share under the 2018 Omnibus Equity Incentive Program. The restricted stock vests one year from the date it was granted. Compensation expense on this restricted stock is expected to be $220,000 over a one year period. In the first nine months of 2019, the Company granted 13,052 shares of restricted stock to non-employee directors at a grant date fair value of $15.96 per share. The restricted stock vested one year from the date it was granted with a compensation expense of $208,000 over such period.
The Company recognized share-based compensation expense on its restricted stock of $165,000 and $160,000 for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, there was unrecognized compensation cost of $55,000 related to unvested restricted stock that is expected to be recognized over a weighted average period of approximately 0.29 years.
Restricted Stock Units
The following is a summary of the Company’s RSU activity during the nine months ended September 30, 2020:
Number of
Shares
Weighted
Average
Price
Outstanding, January 1, 2020300,629 $18.13 
Granted175,869 15.37 
Vested(92,432)18.80 
Forfeited(8,736)18.03 
Outstanding, September 30, 2020375,330 $16.67 
In the first nine months of 2020, the Company granted 175,869 RSUs under the 2018 Omnibus Equity Incentive Plan at a weighted average grant date fair value of $15.37 per share. These units vest within a range of two to three years. A portion of these RSUs will vest subject to certain performance conditions in the applicable restricted stock unit agreement. There are also certain provisions in the compensation program which state that if a recipient of the RSUs reaches a certain age and years of service, the person has effectively earned a portion of the RSUs at that time. Compensation expense on RSUs issued in the first nine months of 2020 is expected to average approximately $901,000 per year over a three-year period. In the first nine months of 2019, the Company granted 141,059 RSUs under the Company’s 2018 Omnibus Equity Incentive Plan at a weighted average grant date fair value of $16.62 per share. Compensation expense on these RSUs is expected to average approximately $781,000 per year over a three-year period.
The Company recognized share based compensation expense of $1.9 million and $1.7 million on RSUs for the nine months ended September 30, 2020 and 2019, respectively. Unrecognized compensation expense related to RSUs was approximately $3.1 million as of September 30, 2020, and that cost is expected to be recognized over a period of 1.46 years.
Stock Options
A summary of the activity under the Company’s stock option plans as of September 30, 2020 is as follows:
Number of
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
(in years)
Aggregate
Intrinsic
Value
Outstanding, January 1, 202031,706 $7.76 0.58$305,120 
Expired(28,940)7.83 
Outstanding, September 30, 20202,766 $6.94 1.32$8,329 
Options exercisable at September 30, 20202,766 $6.94 1.32$8,329 
The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options).
There were no stock option grants in the first nine months of 2020 or 2019. There were no stock options exercised during the first nine months of 2020 and 34,727 stock options were exercised during the first nine months of 2019. The aggregate intrinsic value of stock options exercised during the first nine months of 2019 was $255,000 and resulted in $307,000 in cash receipts. There was no unrecognized compensation expense related to unvested stock options as of September 30, 2020.